Skip to content

Study · Randomized controlled trial · n = 20 · 1991

3 results

The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults.

Schlemmer A, Johansen JS, Pedersen SA, Jørgensen JO, Hassager C, Christiansen C

Clinical endocrinology1 Dec 1991Cited by 55 (Europe PMC)

PMID1769127 (opens in a new tab)DOI10.1111/j.1365-2265.1991.tb00930.x (opens in a new tab)PepBankPUB-01769127
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In GH-deficient adults, GH increased fasting urinary pyridinoline excretion.

    In plain wordsIn GH-deficient adults, GH increased urinary pyridinoline compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseUrinary pyridinoline
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    2 IU/m2 daily · subcutaneous · 4 monthsAs given in this study (human).

    Measurements

    Increase
    287%
    pyridinoline

    Source sentences

    Summary
    GH increased fasting urinary excretion of pyridinoline (287 +/- 123%, P less than 0.001) and deoxypyridinoline (313 +/- 140%, P less than 0.001).
    1 context sentence
    Summary · context
    Randomized, double-blind, placebo-controlled cross-over study. The treatment periods (GH 2 IU/m2 subcutaneously, or placebo daily for 4 months) were separated by a 4-month washout period.PatientsTwenty GH-deficient adults (aged 18-39).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In GH-deficient adults, GH increased fasting urinary deoxypyridinoline excretion.

    In plain wordsIn GH-deficient adults, GH increased urinary deoxypyridinoline compared with placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseUrinary deoxypyridinoline
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    2 IU/m2 daily · subcutaneous · 4 monthsAs given in this study (human).

    Measurements

    Increase
    313%
    deoxypyridinoline

    Source sentences

    Summary
    GH increased fasting urinary excretion of pyridinoline (287 +/- 123%, P less than 0.001) and deoxypyridinoline (313 +/- 140%, P less than 0.001).
    1 context sentence
    Summary · context
    Randomized, double-blind, placebo-controlled cross-over study. The treatment periods (GH 2 IU/m2 subcutaneously, or placebo daily for 4 months) were separated by a 4-month washout period.PatientsTwenty GH-deficient adults (aged 18-39).
  3. 03HumanRandomized controlled trialMechanism

    In GH-deficient adults, GH-induced urinary cross-link increments correlated with increased plasma bone Gla protein.

    In plain wordsIn GH-deficient adults, increases in urinary bone markers were linked to increased blood bone Gla protein during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCross-link increments and bone Gla protein correlation
    Study

    n = 20

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    2 IU/m2 daily · subcutaneous · 4 monthsAs given in this study (human).

    Measurements

    Correlation coefficient
    0.83 to 0.86 r
    cross-links and bone Gla protein

    Source sentences

    Summary
    The GH-induced increment in these parameters correlated with the increase seen in plasma bone Gla protein (r = 0.83-0.86, P less than 0.001).
    1 context sentence
    Summary · context
    Randomized, double-blind, placebo-controlled cross-over study. The treatment periods (GH 2 IU/m2 subcutaneously, or placebo daily for 4 months) were separated by a 4-month washout period.PatientsTwenty GH-deficient adults (aged 18-39).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.